SS-31 Study Explained: Identifying responders to elamipretide in Barth syndrome Hierarchical

Quick answer

For “Identifying responders elamipretide Barth syndrome,” a wearable-device study from the TAZPOWER trial found that machine learning models could cluster Barth syndrome patients by their functional status with 60–93% accuracy, with the highest accuracy for the 6-minute walk test.¹ This is an exploratory analysis intended to help design future trials, not to confirm a treatment effect.¹ Filipino readers should keep that finding tied to the cited study and verify any local product claim separately.

What is SS-31, in plain language?

The practical reading of Identifying responders elamipretide Barth syndrome is specific rather than dramatic. Keep the measured outcome, the comparison, and the study setting attached to one another.

For “Identifying responders elamipretide Barth syndrome,” the source describes a focused result: a wearable-device study from the TAZPOWER trial found that machine learning models could cluster Barth syndrome patients by their functional status with 60–93% accuracy, with the highest accuracy for the 6-minute walk test.¹

Within “Identifying responders elamipretide Barth syndrome,” the population and method are part of the answer: this analysis used data from the 12-patient randomized crossover trial to see if continuous physiological data could identify treatment responders.¹

For “Identifying responders elamipretide Barth syndrome,” the source also narrows the conclusion: this is an exploratory analysis intended to help design future trials, not to confirm a treatment effect.¹

Readers researching SS-31 can view its live catalog details below. The listing identifies the catalog item and is separate from the evidence discussed here.

What did the central study report?

The useful question in this Identifying responders elamipretide Barth syndrome story is not whether the headline sounds impressive. It is whether the population, outcome, and comparison still match the cited source.

For “Identifying responders elamipretide Barth syndrome,” the paper’s main result was that in a phase 3 trial of 218 adults with primary mitochondrial myopathy (PMM), elamipretide did not significantly improve the 6-minute walk distance or total fatigue score compared to placebo over 24 weeks.²

Within “Identifying responders elamipretide Barth syndrome,” the study context keeps the conclusion precise: this was the MMPOWER-3 randomized, double-blind, placebo-controlled trial. The primary endpoints were not met.²

What does the wider evidence add?

For readers following Identifying responders elamipretide Barth syndrome, the order matters: identify the study setting, read the result, then place the limitation beside it.

For “Identifying responders elamipretide Barth syndrome,” the central finding was specific: a post hoc analysis of the MMPOWER-3 trial found that a subgroup of patients with nuclear DNA (nDNA) defects in the mtDNA replisome showed a trend toward improvement on the 6-minute walk test with elamipretide.³

Within “Identifying responders elamipretide Barth syndrome,” that result came from this context: this was a post hoc analysis, meaning it was planned after the trial concluded. The improvement of 25.2 meters versus 2.0 meters for placebo had a p-value of 0.06.³

For “Identifying responders elamipretide Barth syndrome,” the finding should stop here: post hoc analyses are considered exploratory and cannot prove a treatment effect on their own.³

Which limits matter most?

A result becomes easier to trust when the Identifying responders elamipretide Barth syndrome details stay visible. Population, method, outcome, and timeframe all belong near the conclusion.

For “Identifying responders elamipretide Barth syndrome,” the source describes a focused result: a wearable-device study from the TAZPOWER trial found that machine learning models could cluster Barth syndrome patients by their functional status with 60–93% accuracy, with the highest accuracy for the 6-minute walk test.¹

Within “Identifying responders elamipretide Barth syndrome,” the population and method are part of the answer: this analysis used data from the 12-patient randomized crossover trial to see if continuous physiological data could identify treatment responders.¹

For “Identifying responders elamipretide Barth syndrome,” the source also narrows the conclusion: this is an exploratory analysis intended to help design future trials, not to confirm a treatment effect.¹

How does the catalog identity fit?

The practical reading of Identifying responders elamipretide Barth syndrome is specific rather than dramatic. Keep the measured outcome, the comparison, and the study setting attached to one another.

For “Identifying responders elamipretide Barth syndrome,” the paper’s main result was that in a long-term open-label extension of the TAZPOWER trial, patients with Barth syndrome who continued elamipretide showed a cumulative improvement of 96.1 meters on the 6-minute walk test at the 168-week visit.⁴

Within “Identifying responders elamipretide Barth syndrome,” the study context keeps the conclusion precise: this was a 168-week open-label extension following a 28-week randomized trial. Ten patients entered the extension, and eight completed it.⁴

For “Identifying responders elamipretide Barth syndrome,” that result does not erase its main limit: open-label studies lack a placebo control, so the results may be influenced by patient and researcher expectations.⁴

For “Identifying responders elamipretide Barth syndrome,” the study reported that the Philippine FDA Verification Portal separates licensed establishments from registered or notified health products.⁵ For “Identifying responders elamipretide Barth syndrome,” the main limit is equally important: a portal record applies to the exact product or establishment named in that record.⁵

Readers comparing this topic with MOTS-C can view its live catalog details below. It is a separate catalog reference, not a suggested combination.

What should Filipino readers take away?

The useful question in this Identifying responders elamipretide Barth syndrome story is not whether the headline sounds impressive. It is whether the population, outcome, and comparison still match the cited source.

For “Identifying responders elamipretide Barth syndrome,” the central finding was specific: within that replisome subgroup, patients who also had chronic progressive external ophthalmoplegia (CPEO) showed a significant 37.3-meter improvement on the 6-minute walk test with elamipretide compared to a decline in the placebo group.⁶

Within “Identifying responders elamipretide Barth syndrome,” that result came from this context: this was a further analysis of the MMPOWER-3 trial data, focusing on a specific clinical presentation within the nDNA replisome subgroup.⁶

For “Identifying responders elamipretide Barth syndrome,” the finding should stop here: this finding comes from a very specific, small subgroup and requires confirmation in a prospective trial.⁶

For “Identifying responders elamipretide Barth syndrome,” researchers found that WHO states that some falsified medical products can closely resemble genuine products and may require quality-control analysis.⁷ For “Identifying responders elamipretide Barth syndrome,” one caution belongs beside that result: appearance alone cannot authenticate a product or establish a research outcome.⁷

Bottom line

For “Identifying responders elamipretide Barth syndrome,” the clearest reading is that a wearable-device study from the TAZPOWER trial found that machine learning models could cluster Barth syndrome patients by their functional status with 60–93% accuracy, with the highest accuracy for the 6-minute walk test.¹

In the “Identifying responders elamipretide Barth syndrome” discussion, open-label studies lack a placebo control, so the results may be influenced by patient and researcher expectations.⁴ For Filipino readers, the research result and the exact local product record remain separate checks.

That approach keeps SS-31 informative without turning one study into personal advice, a universal promise, or proof about a catalog product.

Frequently asked questions

What is the short answer about SS-31?

For “Identifying responders elamipretide Barth syndrome,” the cited source gives a focused answer: a wearable-device study from the TAZPOWER trial found that machine learning models could cluster Barth syndrome patients by their functional status with 60–93% accuracy, with the highest accuracy for the 6-minute walk test.¹ The conclusion stays tied to that study’s population, method, and measured outcome.

Does one positive result settle the whole topic?

For “Identifying responders elamipretide Barth syndrome,” no single result settles the whole topic. Open-label studies lack a placebo control, so the results may be influenced by patient and researcher expectations.⁴ A useful result can remain narrow without being dismissed or promoted as a universal benefit.

Why does the study context matter?

Within “Identifying responders elamipretide Barth syndrome,” this was the MMPOWER-3 randomized, double-blind, placebo-controlled trial. The primary endpoints were not met.² Changing the population, comparison, formulation, or endpoint would change the question, so those details belong beside the finding.

What should Filipino readers verify?

For “Identifying responders elamipretide Barth syndrome,” in a long-term open-label extension of the TAZPOWER trial, patients with Barth syndrome who continued elamipretide showed a cumulative improvement of 96.1 meters on the 6-minute walk test at the 168-week visit.⁴ Check the exact name and record shown by the official source instead of assuming that a familiar molecule name covers every listing.

Do the SS-31 and MOTS-C cards prove a benefit?

No. In this Identifying responders elamipretide Barth syndrome guide, the cards are live catalog references for navigation. They do not prove study equivalence, turn research into a product claim, or suggest that the two items should be used together.⁸

Sources

Footnotes

1. Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data.. This analysis used data from the 12-patient randomized crossover trial to see if continuous physiological data could identify treatment responders. This is an exploratory analysis intended to help design future trials, not to confirm a treatment effect. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰

2. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.. This was the MMPOWER-3 randomized, double-blind, placebo-controlled trial. The primary endpoints were not met. ↩ ↩² ↩³

3. Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.. This was a post hoc analysis, meaning it was planned after the trial concluded. The improvement of 25.2 meters versus 2.0 meters for placebo had a p-value of 0.06. Post hoc analyses are considered exploratory and cannot prove a treatment effect on their own. ↩ ↩² ↩³

4. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.. This was a 168-week open-label extension following a 28-week randomized trial. Ten patients entered the extension, and eight completed it. Open-label studies lack a placebo control, so the results may be influenced by patient and researcher expectations. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶

5. Philippine FDA Verification Portal; FDA Advisory No. 2023-2238: Utilization of the FDA Verification Portal. Official Philippine regulatory verification service. A portal record applies to the exact product or establishment named in that record. ↩ ↩²

6. Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.. This was a further analysis of the MMPOWER-3 trial data, focusing on a specific clinical presentation within the nDNA replisome subgroup. This finding comes from a very specific, small subgroup and requires confirmation in a prospective trial. ↩ ↩² ↩³

7. WHO laboratory analysis of suspected falsified medical products; WHO laboratory testing for health-product regulation. WHO guidance on suspected falsified medical products and regulatory laboratory testing. Appearance alone cannot authenticate a product or establish a research outcome. ↩ ↩²

8. Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data.; Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.; Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.; Philippine FDA Verification Portal; FDA Advisory No. 2023-2238: Utilization of the FDA Verification Portal. Editorial synthesis of the canonical research records and Philippine verification sources. This synthesis is educational and is not personal medical advice or a product recommendation. ↩